UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of ...

Boehringer Ingelheim announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia ...

Although, preclinical data suggest that the behavioral expression of opioid use is similar between male and female rodents, we do not have conclusive results on sex differences on craving and relapse ...